Changes of endothelin-1 and big endothelin-1 levels and action potential duration during myocardial ischemia-reperfusion in dogs with and without ventricular fibrillation

Journal of Cardiovascular Pharmacology

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Vágó, Hajnalka ^a   Soós, Pál ^a   Zima, Endre ^a   Gellér, László ^a   Keltai, Katalin ^a   Róka, Attila ^a   Kékesi, Violetta ^a   Juhász Nagy, Alexander ^a   Merkely, Béla ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Endothelin; Ischemia reperfusion; Monophasic action potential duration; Ventricular fibrillation

Indexed keywords

ENDOTHELIN 1;

ACTION POTENTIAL; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; CORONARY SINUS; DISEASE COURSE; DOG; EPICARDIUM; FEMALE; FEMORAL ARTERY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; INCIDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ACTION POTENTIALS; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; ENDOTHELIN-1; FEMALE; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; PERICARDIUM; PROTEIN PRECURSORS; TIME FACTORS; UP-REGULATION; VENTRICULAR FIBRILLATION;

EID: 11144338343     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000166299.10443.0c     Document Type: Conference Paper

References (13)

1. Ezra D, Goldstein RJ, Czaja, JF, et al. Lethal ischaemia due to intracoronary endothelin in pigs. Am J Physiol. 1989;257:339-334.
2. Yorikane R, Shiga H, Miyake S, et al. Evidence for direct arrhythmic action of endothelin. Biochem Biophys Res Commun. 1990;73:457-462.
3. Yorikane R, Koike H, Miyake S. Electrophysiological effects of endothelin-1 on canine myocardial cells. J Cardiovasc Pharmacol. 1991;17:S159-S162.
4. Merkely B, Tóth M, Solti F, et al. New ventricular tachycardia model: endothelin-induced triggered arrhythmias in dogs [abstract]. Circulation. 1995;92:3078.
5. Merkely B, Gellér L, Tóth M, et al. Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs. J Cardiovasc Pharmacol. 1998;31:S437-S439.
6. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
7. Brunner F, Dutoit EF, Opie LH. Endothelin release during ischemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol 1992;24:1291-1305.
8. Stewart DJ, Kubac G, Costello KB, et al. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
9. Battistini B, Kingma JG. Changes in plasma levels of ET-1 and its precursor, Big ET-1, in the arterial and venous circulation following double myocardial ischemia-reperfusion injury in dogs. J Cardiovasc Pharmacol. 2000;36(suppl 1):S215-S220.
10. Duru F, Barton M, Luscher TF, et al. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res. 2001;49:272-280.
11. Merkely B, Vágó H, Kiss O, et al. Expressed monophasic action potential alternans before the onset of ventricular arrhythmias induced by intracoronary bolus administration of endothelin-1 in dogs. Clin Sci. 2002;103(suppl 48):219S-222S.
12. Curtis MJ, Pugsley MK, Walker MJA. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res. 1993;27:703-719.
13. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992; 267:16066-16068.